Upstream Biosciences Inc. Marktpotential von 1 Bil
OttomanRosendahl : Upstream Biosciences Inc. Marktpotential von 1 Bil
Upstream Biosciences Inc. (OTC BB: UPBS) May Hold Key to Early Detection and Effective Treatment of Some Cancers
Upstream Biosciences Inc. (OTC BB: UPBS) is an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response. This exciting young company already has filed three provisional patents and an amazing proprietary discovery pipeline that should continue to yield a stream of potentially priceless intellectual property in the cancer segment of the SUPER HOT biotech industry for years to come.
UPBS's initial genetic predisposition markers (biomarker tests) could be the answer the overwhelmed healthcare community has been searching for. The company?s first two tests are targeted against liver and prostate cancer. These two tests alone are estimated to have a market potential of over $1 BILLION!
UPBS?s Liver Cancer Susceptibility Test (US Patent # 60/767170).
|?||UPBS?s Prostate Cancer Susceptibility Test (US Patent # 60/767368).|
These tests will utilize genetic variations that determine a patients? risk of getting liver or prostate cancer. These tests will prove to be invaluable.
Best of all, most of the big guys on Wall Street don?t even know about UPBS?s astronomical potential yet, so the company?s stock price remains at bargain basement prices?for now.
Biotech Stocks Now Worth
Hundreds of Billions of Dollars
Over the last decade or so select biotechnology companies leading the charge in the vital field of early cancer detection and prediction have enjoyed tremendous success. The biotech sector has grown to be worth hundreds of Billions of dollars. As a matter of fact, the top ten publicly traded biotechnology companies now have a combined market cap of an astounding $285 BILLION! That is BIG MONEY.
Many biotech companies have watched their stocks go up by 500%, 1,000%, 1,500% or more as they got closer to tests or treatments for costly diseases like cancer. Obviously, it is way too late to take advantage of the incredible growth experienced by industry leaders such as Amgen ($87 billion), Genentech ($85 billion) or Gilead ($31 billion), but?
it could be the absolute best time to get in on the ground floor with a company like UPBS that looks like it is about to explode and could experience the same kind of growth that the industry giants have. That is why you must read this special report carefully and TAKE IMMEDIATE ACTION!!!
UPBS also Helps Determine the Most Effective Treatments for Existing Cancers
In addition to the two revolutionary predisposition cancer tests it already has, UPBS has also developed a novel test for predicting the impact of genetic variations on patient drug reaction ? how each patient will react to different cancer drugs, thus increasing the likelihood that their cancers can be treated effectively.
|UPBS?s Drug Response Diagnostics (US Patent # 60/767077) could end up being the company?s most profitable discovery yet because of the enormous number of people that are diagnosed with cancer every year.|
Hundreds of thousands of patients worldwide die every year because they don?t get the right treatment for the cancers they have. That number could be reduced significantly if doctors had a tool that allowed them to predetermine what treatments would be most beneficial to each patient before they started experimenting with different drugs and procedures.
are Commanding HUGE Prices?
UPBS could be next.
When a young company starts making breakthroughs that have the potential to catapult them into the biotech stratosphere, they quickly become excellent acquisition targets. This means that their prices go up and go up fast!!! UPBS is currently trading at about $.85 a share and its total market cap is only approximately $40 Million. With its three breakthrough tests that hold the potential for $1 Billion or more in potential revenues, UPBS could soon become ripe for a major takeover. Takeovers in the biotech and pharmaceutical industry have become red hot lately and the acquisition process are going through the roof!!!
Just last month, pharmaceutical giant Merck & Co. paid an eye-popping $1.1 BILLION to buy Sirna Therapeutics, a tiny biotechnology firm that is developing drugs using the so-called RNA interference technology, even though Sirna has yet to bring a single product to market. This was more than double Sirna?s share price at the time of the offer.
This comes just about two weeks after Eli Lilly and Co. said it planned to buy Icos Corp., which co-markets its drug Cialis, for $2.1 BILLION in cash. Also in October, Genzyme Corp. outbid Millennium Pharmaceuticals for AnorMed Inc., agreeing to pay $580 million in cash for the development-stage company. And the list goes on and on. The buyout frenzy has gotten so competitive that Schering-Plough Corp. Chief Executive Officer Fred Hassan said recently that the prices being fetched in the recent wave of big pharmaceutical takeover bids are "breath-taking."
Will UPBS be the next company to be acquired at a huge premium by one of the industry giants? It is still too early to say for sure. But if it does happen, those investors that were smart enough to see the early signs could become millionaires.
8 Major Reasons to Own
Upstream Biosciences (UPBS) today!
|1.||UPBS already holds two provisional patents for biomarker tests for the early detection of predisposition to develop liver or prostate cancers.|
|2.||UPBS also has a provisional patent for a drug response test that can tell doctors what drugs will work best for cancer patients.|
|3.||UPBS has an amazing proprietary discovery pipeline that should continue to yield a stream of potentially priceless intellectual property in the cancer segment of the SUPER HOT biotech industry.|
|4.||There is a growing feeding frenzy in the biotech/pharmaceutical industry where leading companies are buying up young companies like UPBS with promising technologies for huge premiums.|
|5.||UBPS has an extremely specialized management team and advisory board with tons of experience in developing breakthrough technologies and bringing them to market.|
|6.||UPBS possesses technologies that could be worth over $1 Billion and more in the pipeline.|
|7.||Based on current industry P/E ration, with just $10-30 million in profits, UPBS?s share price could go up by 1,000-5,000% or more.|
|8.||With very little exposure on Wall Street, a minimal share price and the potential to produce massive revenues, UBPS looks to be a sleeping giant waiting to explode.|
With just roughly 45 million shares outstanding, if this company comes anywhere close to living up to its expectations, this stock could literally go through the roof.
For example, by generating just $10?$20 million in profit, relying on current industry average P/E ratios that range from the single to quadruple digits, this stock could shoot up from the $.80 range to $30.00?$50.00 or more!!!
This means that under that scenario, a simple $10,000 investment could potentially turn into $400,000 to $700,000 or more. That?s truly an amazing prospect!
UPBS could be the # 1 Pick of the Year!!!
UPBS clearly looks like one of the very best undiscovered companies in a long time, but it may not stay that way. This company will start attracting more attention from the biotechnology and medical industries as well as Wall Street.
So whatever you do, don?t delay. Start your due diligence immediately. Call your broker or financial advisor about Upstream Biosciences (UPBS). It could be the most important call you make in your lifetime!
OttomanRosendahl : Die Tage sollten die Zahlen doch kommen oder ?
Seit über einem Monat nichts gehört über Upstream
Upstream Biosciences' Potential Tropical Disease Treatments Demonstrate Promising Signs of Efficacy at McGill University
Tuesday October 7, 9:00 am ET
Second Generation of Drug Candidates Show in Vitro Efficacy Against Leishmaniasis and Trypanosomiasis
VANCOUVER, BC--(MARKET WIRE)--Oct 7, 2008 -- Upstream Biosciences Inc. (OTC BB:UPBS.OB - News) today announced that its second generation of novel antiparasitic agents demonstrated in vitro efficacy against both Leishmaniasis and Trypanosomiasis. Upstream's novel compounds were tested by Dr. Armando Jardim at the Institute of Parasitology of McGill University in Montreal, Quebec, Canada. Upstream continues to collaborate with McGill to perform further testing on its potential tropical disease treatments. The Institute of Parasitology is recognized internationally for its research on infectious parasitic diseases. "We are extremely excited that our second generation drug candidates have been validated by a world renowned institute," said Joel Bellenson, Chief Executive Officer of Upstream. "This is a significant milestone for the company and demonstrates Upstream's ability to optimize its compounds quickly and cost effectively." Upstream's proprietary drug discovery platform utilizes chemoinformatics which combines chemistry and computer-aided design to accelerate the speed and reduce the cost of drug discovery. "I am excited about the initial results of our testing. I look forward to continuing our collaboration with Upstream on their promising new drugs. New treatments are desperately needed to treat these devastating diseases and Upstream's approach may provide a new strategy to tackling these infectious agents," said Dr. Jardim. Upstream's first generation of drug candidates have successfully demonstrated in vitro anti-parasitic activity, in vitro human cell safety, and in vivo (in animals) safety for Leishmaniasis, Trypanosomiasis and malaria. The Company's first generation drug candidates are currently being tested for in vivo (in animals) efficacy against Leishmaniasis and Trypanosomiasis at Makerere University in Kampala, Uganda. Leishmaniasis, Trypanosomiasis (African sleeping sickness), and Malaria are caused by parasites that have developed resistance to a number of first line drugs that are available to treat these diseases. Leishmaniasis afflicts millions of people living in Africa, India, and the Middle East. Similarly, it is estimated 60 million people and 50 million cattle in sub-Saharan Africa are infected or are at risk of contracting Trypanosomiasis. According to the World Heath Organization, about 40% of the world's population is at risk for contracting Malaria. These diseases are expected to be included in the United States Food and Drug Administration's proposed priority review voucher program designed to provide financial incentive to companies developing treatments. About Upstream Biosciences, Inc. Upstream Biosciences is focused on developing and commercializing drug candidates to treat tropical diseases, including Leishmaniasis, Trypanosomiasis (African sleeping sickness) and Malaria. Caused by parasites that have developed resistance to available treatments, these diseases afflict millions of people living in Asia, Africa, and Middle East with death, illness, malnourishment and economic hardship. Upstream's drug candidates are generated using its proprietary computer-assisted drug discovery process. The Company's lead drug candidates have demonstrated anti-parasitic efficacy in vitro and positive safety data in animals.